title: The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review.
abstract: Initially described as key regulators in metabolic bone disease osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and RANK ligand (RANKL) have also been discriminated as regulators in immunologic function. Cardiovascular diseases (CVD) develop over many years in life and are often triggered by inflammatory processes within the vessel wall that lead to vascular remodeling. Recently some study groups have described OPG as a prognostic parameter for mortality and morbidity in cardiovascular patients.
authors.affiliation: Division of Cardiac Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
authors.forename: Daniela-Eugenia
authors.initials: DE
authors.lastname: Malliga
authors.forename: Doris
authors.initials: D
authors.lastname: Wagner
authors.forename: Astrid
authors.initials: A
authors.lastname: Fahrleitner-Pammer
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001161:Arteriosclerosis / Q000503:physiopathology; D015519:Bone Density / Q000502:physiology; D001862:Bone Resorption / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D003327:Coronary Disease / Q000503:physiopathology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006333:Heart Failure / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010010:Osteoclasts / Q000502:physiology; D010024:Osteoporosis / Q000503:physiopathology; D053244:Osteoprotegerin; D011379:Prognosis; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D012737:Sex Factors; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology; D055815:Young Adult
chemical_list: D012739:Gonadal Steroid Hormones; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505688:TNFSF11 protein, human